ESH Video

Conference on MYELODYSPLASTIC SYNDROMES

Conference on MYELODYSPLASTIC SYNDROMES
October 22 - October 25, 2009 - Mandelieu, France
Chairs :

Information

Programme

Thursday, October 22, 2009

Session 1 BONE MARROW FAILURE AND CHILDHOOD MDS - Chair: H. Hasle
14h00-14h45 Pathophysiologic links between marrow failure, genomic instability and clonal évolution N. Young (Bethesda)
14h45-15h30 Childhood MDS and JMML; biology, diagnosis and treatment H. Hasle (Aarhus)
15h30-16h00 Cases and questions to panel Panel
16h00-16h30 Coffee break
Session 2 DIAGNOSTIC WORK-UP OF MDS - Chair: A. Porwit
16h30-17h00 Diagnosis and WHO 2008 classification of MDS A. Porwit (Stockholm)
17h00-17h30 Cytogenetics and molecular genetics in MDS B. Schlegelberger (Hannover)
17h30-17h50 Role of flow cytometry in MDS diagnostics A.A. van de Loosdrecht (Amsterdam)
17h50-18h10 The application of array-based technology in MDS diagnostics A. Pellagatti (Oxford)
18h10-18h30 New aspects of MDS and “not yet MDS” morphology B. Bain (London)
18h30-19h00 Cases and questions to panel Panel
19h30-20h30 Posters and welcome reception
20h30 Dinner
Friday, October 23, 2009
Session 3 EPIDEMIOLOGY AND CLINICAL EVALUATION OF MDS - Chair: L. Malcovati
09h00-09h30 Epidemiology

D. Bowen (Leeds)

09h30-10h00 Clinical presentation M. Jadersten (Stockholm)
10h00-10h30 Prognosis and risk assessment L. Malcovati (Pavia)
10h30–11h00 Cases and questions to panel A. Porwit (Stockholm) &
E. Hellström-Lindberg (Stockholm)
11h00-11h30 Coffee Break
Session 4 MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS - Chair: M. Cazzola
11h30-12h00 Chronic myelomonocytic leukaemia D. Bowen (Leeds)
12h00-12h20 TET2 mutations in MDS and MPNs M. Fontenay (Paris)
12h20-12h40 TET2 mutations in MDS and MPNs

J.H. Janssen (Nijmegen)

12h40-13h00 Refractory anemia with ringed sideroblasts and excessive thrombocytosis

M. Cazzola (Pavia)

13h00-14h30 Lunch discussions at defined tables
Session 5

OVERLAPPING SYNDROMES - Chair: D. Bowen

14h30-15h00 MDS with bone marrow fibrosis

L. Malcovati (Pavia)

15h00-15h30 Therapy related MDS P. Fenaux (Paris)
15h30-16h00 NPM1 – role in AML and MDS C. Mecucci (Perugia)
16h00-16h30 Coffee break
Session 6

MDS RESEARCH. WHAT HAVE WE LEARNED? - Chair: J. Maciejewski

16h30-17h00 MDS research

J. Maciejewski (Cleveland)

17h00-17h30 Epigenetic studies K. Gronbaeck (Copenhagen)
18h00-18h30 Animal models – genetically modified mice R.A. Padua (Paris)
18h30-19h00 Somatically modified cell and animal models A. Karsan (Vancouver)
18h30-19h00 Questions to panel
20h00-21h00 Poster presentation
21h00-22h30 Dinner
Saturday, October 24, 2009
Session 7 PATHOPHYSIOLOGY - Chair: P. Fenaux
09h00-09h30 Apoptosis and erythroid failure in low-risk MDS E. Hellström-Lindberg (Stockholm)
09h30-10h00 Molecular biology and genetic pathways in MDS J. Maciejewski (Cleveland)
10h00-10h30 Molecular biology and genetic pathways in low-risk MDS M. Fontenay (Paris)
10h30-11h00 Clonal evolution and leukaemic transformation

S. Boehrer (Paris)

11h00-11h30 Coffee break
Session 8 BIOLOGY AND TREATMENT OF 5q-SYNDROME - Chair: A. Karsan
11h30-12h00 The molecular pathogenesis of MDS with the del (5q) J. Boultwood (Oxford)
12h00-12h20 Treatment of  5q-; the pro-lenalidomide view P. Fenaux (Paris)
12h20-12h40 Treatment of  5q-; the con-lenalidomide view M. Jadersten (Stockholm)
12h40-13h00 Treatment of 5q-; cases and panel discussion Panel
13h00-14h00 Lunch discussions at defined tables
Session 9 SUPPORTIVE CARE IN MDS - Chair: M. Cazzola
14h00-14h30 Transfusion therapy in MDS L. Malcovati (Pavia)
14h30-15h00 Iron metabolism and transfusion iron overload M. Cazzola (Pavia)
15h00-15h20 Treatment of transfusion iron overload in MDS; the pro-chelation view C. Rose (Lille)
15h20-15h40 Treatment of transfusion iron overload in MDS; the con-chelation view D. Bowen (Leeds)
15h40-16h00 Management and treatment of thrombocytopenia G. Garcia-Manero (Houston)
16h00-16h30 Coffee Break
Session 10 CURATIVE TREATMENT - Chair: T. De Witte
16h30-17h00 Ablative SCT ± preceding chemotherapy T. De Witte (Nijmegen)
17h00-17h30 Non myelomablative stem cell transplantation N. Kroeger (Hamburg)
17h30-18h00 Treatment of paediatric MDS C. Niemeyer (Freiburg)
18h00-18h30 Cases and questions to panel Panel
20h30 Conference Dinner and Jazz Music

Sunday, October 25, 2009

Session 11 TREATMENT OF LOW-RISK MDS - Chair: E. Hellstrom-Lindberg
08h30-09h00 Growth factor treatment of low-risk MDS E. Hellström-Lindberg (Stockholm)
09h00-09h20 Immunosupression in low-risk MDS N. Young (Bethesda)
09h20-09h40 Low-risk MDS: ongoing trials at clinicaltrials.gov M. Cazzola (Pavia)
09h40-10h30 Leukaemia Net Guidelines and cases low-risk MDS Panel
10h00-10h30 Coffee break
Session 12 NON-CURATIVE TREATMENT OF HIGH-RISK MDS - Chair: G. Garcia-Manero
10h30-10h50 Induction chemotherapy and low-dose chemotherapy M. Lübbert (Freiburg)
10h50-11h20 Azacytidine in MDS P. Fenaux (Paris)
11h20-11h40 Decitabine in MDS M. Lübbert (Freiburg)
11h40-12h10 High-risk MDS: HIDACi and ongoing trials at clinicaltrials.gov G. Garcia-Manero (Houston)
12h10-13h00 Leukaemia Net Guidelines and cases high-risk MDS Panel
13h00 Adjourn Chairs

Abstract submission

Symposia

Accommodation

Venue

Corporate partners

Scholarship

Workshop

Registration